These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33773495)

  • 1. Report on 2020 Safe to Touch Consensus Conference on Hazardous Drug Surface Contamination.
    Gabay M; Johnson P; Fanikos J; Amerine L; Kienle P; Olsen M; Roussel C; Moody ML
    Am J Health Syst Pharm; 2021 Aug; 78(17):1568-1575. PubMed ID: 33773495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Third Consensus Development Conference on the Safety of Intravenous Drug Delivery Systems-2018.
    Gabay M; Hertig JB; Degnan D; Burger M; Yaniv A; Mclaughlin M; Lynn Moody M
    Am J Health Syst Pharm; 2020 Jan; 77(3):215-220. PubMed ID: 31811297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leveraging a multidisciplinary oversight committee to ensure USP <797> and <800> compliance at a Veterans Affairs health system.
    Wrzesniewski CE; Park HK
    Am J Health Syst Pharm; 2022 Feb; 79(4):276-282. PubMed ID: 34724546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying health-system pharmacy operational process categories and corresponding tasks across a diverse health system using a modified Delphi process.
    Zeeman JM; Petersen AE; Colmenares EW; Schenkat DH; Vest MH
    Am J Health Syst Pharm; 2022 Jun; 79(13):1070-1078. PubMed ID: 35247263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A practical approach to assess the hazardous exposure potential of investigational drugs.
    McLeod EN; Fillis CJ; Blind JE
    Am J Health Syst Pharm; 2020 Apr; 77(9):697-700. PubMed ID: 34278414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH).
    Valero-García S; González-Haba E; Gorgas-Torner MQ; Alonso-Herreros JM; Cercós Lletí AC; Poveda-Andrés JL; Calleja-Hernandez MÁ; Delgado-Sánchez O
    Farm Hosp; 2021 Mar; 45(2):96-107. PubMed ID: 33709894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surface wipe sampling for antineoplastic (chemotherapy) and other hazardous drug residue in healthcare settings: Methodology and recommendations.
    Connor TH; Zock MD; Snow AH
    J Occup Environ Hyg; 2016 Sep; 13(9):658-67. PubMed ID: 27019141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on safe handling of hazardous drugs: the advice of experts.
    Power LA; Anderson RW; Cortopassi R; Gera JR; Lewis RM
    Am J Hosp Pharm; 1990 May; 47(5):1050-60. PubMed ID: 2186622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hazardous Drug Contamination of Drug Preparation Devices and Staff: A Contamination Study Simulating the Use of Chemotherapy Drugs in a Clinical Setting.
    Call E; Bill B; McLean C; Call N; Bernkopf A; Oberg C
    Hosp Pharm; 2017 Sep; 52(8):551-558. PubMed ID: 29276288
    [No Abstract]   [Full Text] [Related]  

  • 10. Longitudinal evaluation of environmental contamination with hazardous drugs by surface wipe sampling.
    Sessink PJ; Tans B; Spriet I; Devolder D
    J Oncol Pharm Pract; 2024 Oct; 30(7):1181-1185. PubMed ID: 38115732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and evaluation of a novel product to remove surface contamination of hazardous drugs.
    Cox J; Speed V; O'Neal S; Hasselwander T; Sherwood C; Eckel SF; Zamboni WC
    J Oncol Pharm Pract; 2017 Mar; 23(2):103-115. PubMed ID: 26673538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of a decontamination procedure in a pharmacy buffer room contaminated by 5 antineoplastic agents.
    Arpino P; Yeomelakis J; Oommen A
    Am J Health Syst Pharm; 2020 Dec; 77(24):2081-2088. PubMed ID: 33150407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing recommendations for the safe handling of oral anti-cancer drugs in community pharmacies: A pan-Canadian consensus approach.
    Vu K; Emberley P; Brown E; Abbott R; Bates J; Bourrier V; Djordjevic K; Greenall J; Leung M; Pasetka M; Paquet L; Logan H
    J Oncol Pharm Pract; 2019 Apr; 25(3):674-688. PubMed ID: 30200843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns and characteristics associated with surface contamination of hazardous drugs in hospital pharmacies.
    Salch SA; Zamboni WC; Zamboni BA; Eckel SF
    Am J Health Syst Pharm; 2019 Apr; 76(9):591-598. PubMed ID: 31361828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surface contamination of hazardous drug pharmacy storage bins and pharmacy distributor shipping containers.
    Redic KA; Fang K; Christen C; Chaffee BW
    J Oncol Pharm Pract; 2018 Mar; 24(2):91-97. PubMed ID: 27856922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New approaches to wipe sampling methods for antineoplastic and other hazardous drugs in healthcare settings.
    Connor TH; Smith JP
    Pharm Technol Hosp Pharm; 2016 Sep; 1(3):107-114. PubMed ID: 28459100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Creation of a regional hazardous drug handling task force.
    Duty A; Robinson J; Bahmandar D; Hanson N; Lucas AJ
    Am J Health Syst Pharm; 2021 Jun; 78(13):1233-1237. PubMed ID: 33895790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques.
    Harrison BR; Peters BG; Bing MR
    Am J Health Syst Pharm; 2006 Sep; 63(18):1736-44. PubMed ID: 16960258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surface contamination of counting tools after mock dispensing of cyclophosphamide in a simulated outpatient pharmacy.
    Chaffee BW; Lander MJ; Christen C; Redic KA
    J Oncol Pharm Pract; 2019 Jan; 25(1):85-93. PubMed ID: 29592766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spatial and Temporal Variability in Antineoplastic Drug Surface Contamination in Cancer Care Centers in Alberta and Minnesota.
    Jeronimo M; Arnold S; Astrakianakis G; Lyden G; Stewart Q; Petersen A; Chambers C; Malard Johnson D; Zimdars E; Kaup H; Davies HW
    Ann Work Expo Health; 2021 Aug; 65(7):760-774. PubMed ID: 33889938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.